Drugs / rhPTH(1-31)NH2
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01321723 | Feb → Oct 2011 | postmenopausal osteoporosis | Unigene Laboratories Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rhPTH(1-31)NH2 | “The objective of this study was to assess the pharmacokinetics of a PTH analog (rhPTH(1-31)NH2) in a novel oral tablet formulation and to compare them to subcutaneously...” PMID 23719683 ↗ Nov 2013 |
| Modality | Peptide | “A recombinant 1-31 amino acid fragment of PTH.” NCT01321723 ↗ |
| Route | Oral | “Orally formulated recombinant human PTH(1-31)NH(2)” PMID 23234813 ↗ Dec 2012 |